- Home
- DGX
as 03-25-2025 10:34am EST
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
| Founded: | 1967 | Country: | United States |
| Employees: | N/A | City: | SECAUCUS |
| Market Cap: | 19.2B | IPO Year: | 1996 |
| Target Price: | $178.38 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 7.69 | EPS Growth: | 2.67 |
| 52 Week Low/High: | $125.42 - $178.87 | Next Earning Date: | 04-22-2025 |
| Revenue: | $9,872,000,000 | Revenue Growth: | 6.70% |
| Revenue Growth (this year): | 10.28% | Revenue Growth (next year): | 3.84% |
Stock Insider Trading Activity of Quest Diagnostics Incorporated (DGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| PREVOZNIK MICHAEL E | DGX | SVP & General Counsel | Mar 17 '25 | Sell | $170.00 | 4,643 | $789,310.00 | 38,117 | |
| Doherty Catherine T. | DGX | EVP, Regional Businesses | Mar 5 '25 | Sell | $174.13 | 5,370 | $935,078.10 | 68,068 | |
| Doherty Catherine T. | DGX | EVP, Regional Businesses | Mar 3 '25 | Sell | $175.79 | 716 | $125,865.64 | 68,068 | |
| PREVOZNIK MICHAEL E | DGX | SVP & General Counsel | Mar 3 '25 | Sell | $175.79 | 592 | $104,067.68 | 38,117 | |
| Doherty Catherine T. | DGX | EVP, Regional Businesses | Feb 26 '25 | Sell | $172.61 | 824 | $142,230.64 | 68,068 | |
| PREVOZNIK MICHAEL E | DGX | SVP & General Counsel | Feb 26 '25 | Sell | $172.61 | 528 | $91,138.08 | 38,117 | |
| Plewman Patrick | DGX | SVP for Diagnostic Services | Feb 19 '25 | Sell | $169.71 | 320 | $54,307.20 | 18,082 | |
| Doherty Catherine T. | DGX | EVP, Regional Businesses | Feb 19 '25 | Sell | $170.35 | 1,434 | $244,514.86 | 68,068 | |
| PREVOZNIK MICHAEL E | DGX | SVP & General Counsel | Feb 19 '25 | Sell | $170.99 | 604 | $103,277.96 | 38,117 | |
| DELANEY MARK E | DGX | SVP & Chief Commercial Officer | Feb 5 '25 | Sell | $164.30 | 403 | $66,214.15 | 4,624 |
Latest Quest Diagnostics Incorporated News
DGX Breaking Stock News: Dive into DGX Ticker-Specific Updates for Smart Investing
Argus Research
a day ago
Weekly Stock List
Insider Monkey
2 days ago
Quest Diagnostics (DGX) and Google Cloud to Transform Healthcare Data with AI
Zacks
4 days ago
DGX Stock Set to Benefit From New Google Cloud Partnership
TipRanks
5 days ago
Autodesk in proxy fight, General Mills reports mixed Q3: Morning Buzz
Simply Wall St.
5 days ago
Quest Diagnostics' (NYSE:DGX) Dividend Will Be Increased To $0.80
MT Newswires
5 days ago
Baird Adjusts Price Target on Quest Diagnostics to $191 From $190, Keeps Outperform Rating
Zacks
6 days ago
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight
MT Newswires
6 days ago
Quest Diagnostics Lowers Q1 Outlook, Reaffirms 2025 Guidance
Compare DGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DGX Quest Diagnostics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.